Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJiazhuo LiuCHChuan He

Discussion

Loading...

Member takes

Overview

Retrospective analysis reports orelabrutinib improved safety profile and 96.7% progression-free survival in chronic lymphocytic leukemia patients, suggesting effectiveness as therapy.

Key Points

  • Orelabrutinib monotherapy achieved a 96.7% disease control rate among 30 patients with chronic lymphocytic leukemia.
  • Overall response rate recorded was 93.3%, resulting in 4 complete responses and 24 partial responses.
  • Retrospective study noted no adverse events related to Bruton's tyrosine kinase inhibitor off-target activity.
  • Findings highlight the need for further prospective studies to validate orelabrutinib's clinical benefits.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dbfdhttps://doi.org/10.1182/blood-2025-7422
View Full Paper
Ask AI
Bookmark
Share